NuVasive, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, has reported fourth quarter 2010 revenue of $129.3 million, representing a 20.9 percent increase over the $106.9 million for the fourth quarter 2009, according to a company news release.
Chairman and CEO Alex Lukianov attributes the company's success to its line of XLIF technology. In addition to 4Q results, NuVasive has reported full-year 2010 financial results. Total revenue for 2010 amounted to $478.2 million, up 29.1 percent from the full-year 2009.
The company received a $2 million settlement from Orthofix during the fourth quarter from to a patent dispute over orthopedic technology. The company also received FDA 510(k) clearance for the Spherx II-Mas deformity spinal system during the fourth quarter.
Read the news release about NuVasive's financial results.
Read other coverage about company financial reports:
- LDR Announces 77% Sales Growth for U.S. Operations
- Alphatec Spine Reports 4Q Revenue of $46M, 38.4% Increase
- Symmetry Medical Reports 4Q Revenue of $96M, 26% Increase
Chairman and CEO Alex Lukianov attributes the company's success to its line of XLIF technology. In addition to 4Q results, NuVasive has reported full-year 2010 financial results. Total revenue for 2010 amounted to $478.2 million, up 29.1 percent from the full-year 2009.
The company received a $2 million settlement from Orthofix during the fourth quarter from to a patent dispute over orthopedic technology. The company also received FDA 510(k) clearance for the Spherx II-Mas deformity spinal system during the fourth quarter.
Read the news release about NuVasive's financial results.
Read other coverage about company financial reports:
- LDR Announces 77% Sales Growth for U.S. Operations
- Alphatec Spine Reports 4Q Revenue of $46M, 38.4% Increase
- Symmetry Medical Reports 4Q Revenue of $96M, 26% Increase